Amlexanox: what it is and what the evidence says
Not a peptide: a small molecule that inhibits the kinases TBK1 and IKKe, which are involved in obesity-associated inflammation.
Last reviewed: August 16, 2026 · How we verify this
The ground it plays on
Metabolism is not a single lever. Talk about metabolic compounds usually collapses three separate mechanisms into one word. Appetite regulation is one. How well cells respond to insulin is another, and largely independent of the first. Mobilizing stored fat is a third. A compound may act on one and leave the other two untouched, so knowing which one is the difference between understanding a molecule and reciting its name.
What it is studied for
Mouth ulcers (approved); metabolism (experimental).
There is a distinction that almost always gets lost. A compound being studied for something is not the same as achieving it. And even where it works in a dish or in a mouse, that says little about whether it works in a person or whether the benefit is worth the risk. The section below therefore carries more weight than everything above it.
What the human evidence says
It has controlled trials that led to its approval as an oral paste for canker sores (FDA, 1996) and as a tablet for asthma and allergic rhinitis (Japan, 1987). In metabolism there is one randomized, double-blind, placebo-controlled trial in Cell Metabolism (2017), with 42 adults with type 2 diabetes and obesity, in which HbA1c and fructosamine fell; the response was clear in about a third of participants, those with the highest baseline inflammation.
The limitation that matters most
The metabolic effect was seen in a subgroup, within a single small, short trial that has not yet been replicated. Still missing are a validated test to anticipate who responds, long-term safety data with sustained oral use, and the results of the follow-up studies the authors proposed.
Regulatory status
Approved by the FDA in 1996 as a 5% oral paste (Aphthasol) for recurrent aphthous stomatitis and in 2004 as an oral patch; both now appear as discontinued in the FDA registry. In Japan it was approved in 1987 as tablets for bronchial asthma and allergic rhinitis, and it left the market in 2017. No approval for obesity, diabetes, or fatty liver. It is not listed by name on the WADA list; anyone competing under anti-doping rules should confirm it with their authority.
Status can change and varies by country. Always verify the rules in force where you live before drawing conclusions.
Cautions and context
Its metabolic use is off-label and only a subgroup of patients responded.
With type 2 diabetes or fatty liver under treatment, it is reviewed with an endocrinologist before starting, because it can add to glucose-lowering drugs and calls for follow-up lab work.
What this page cannot give you
A reference page can take you this far. You know what Amlexanox is and where its research stands, which already puts you ahead of most readers. Four questions remain that no encyclopedia can answer for you, because the answers depend on your own situation:
- What would you measure beforehand, so that later you could tell whether anything actually changed?
- What would you watch along the way, and how consistently?
- What would you ask a professional, and in how much detail, so you do not walk out with a textbook answer?
- What would make you stop?
That is what the course is for
PeptiXtreme is ${CIF.LECCIONES} lessons that hand out no numbers. Each one ends with your starting point, what to watch along the way, the specific questions you take to a professional and the signals that mean stop. It includes per-module exams, a Certificate of Completion with a verifiable certificate ID, a Progress Tracker to follow how you are doing, and a human advisor you can actually write to.
See the course → Or measure your judgment, freeReferences
Every entry links to its record on PubMed, the US National Library of Medicine database. Open them and check. We would rather have a reader who verifies than one who takes our word for it.
- Inhibition of IKKε and TBK1 Improves Glucose Control in a Subset of Patients with Type 2 Diabeteshuman Cell Metab · 2017 · PMID 28683283 →
- An inhibitor of the protein kinases TBK1 and IKK-ε improves obesity-related metabolic dysfunctions in micepreclinical Nat Med · 2013 · PMID 23396211 →
- A subcutaneous adipose tissue-liver signalling axis controls hepatic gluconeogenesishuman Nat Commun · 2015 · PMID 25581158 →
- Treatment of recurrent aphthous stomatitis. A literature reviewreview J Clin Exp Dent · 2014 · PMID 24790718 →
Was this page useful?
Research moves, and when something relevant changes we update the page. If you want to hear about it for Amlexanox or any other compound, leave your email. The introductory guide comes with it. No spam, no list-selling; one click to unsubscribe.
Frequently asked questions
What is Amlexanox?
Not a peptide: a small molecule that inhibits the kinases TBK1 and IKKe, which are involved in obesity-associated inflammation. It is studied within the area of metabolic.
Is there human evidence for Amlexanox?
It has controlled trials that led to its approval as an oral paste for canker sores (FDA, 1996) and as a tablet for asthma and allergic rhinitis (Japan, 1987). In metabolism there is one randomized, double-blind, placebo-controlled trial in Cell Metabolism (2017), with 42 adults with type 2 diabetes and obesity, in which HbA1c and fructosamine fell; the response was clear in about a third of participants, those with the highest baseline inflammation.
Is it approved by any health agency?
Approved by the FDA in 1996 as a 5% oral paste (Aphthasol) for recurrent aphthous stomatitis and in 2004 as an oral patch; both now appear as discontinued in the FDA registry. In Japan it was approved in 1987 as tablets for bronchial asthma and allergic rhinitis, and it left the market in 2017. No approval for obesity, diabetes, or fatty liver. It is not listed by name on the WADA list; anyone competing under anti-doping rules should confirm it with their authority.
What is the dose of Amlexanox?
We do not publish dosages. This is not an oversight. No single figure works for everyone: the regimen depends on a person's medical history, on whatever medication they already take, and on the goal they are chasing, which is something a professional weighs with the case in front of them. What you can build is the ability to walk into that appointment knowing what to ask.
Where can I learn to evaluate this properly?
This page tells you what Amlexanox is and what the evidence says. The PeptiXtreme course teaches the other half: what you would measure before considering anything, what you would watch, the specific questions you would take to a professional and when you would stop.